CUSTOMER SUPPORT CUSTOMER SUPPORT +91-9999-696-045

fund search

Individually analyse each scheme and narrow your options further Every minute detail you need to know about scheme of your choice from asset holdings, best and worst performance and fund returns to competitor analysis; is available in the Fund card.
Using this report card, you can gather vital information regarding the future health of the scheme by analysing the top 10 companies and sectors it invests in. You can also track the fund management’s track record and analyse the philosophy behind scheme’s holdings. All the parameters in the fund card are extremely important and can go a long way in helping you decide which scheme to invest your money.

NAV As on Jun-01-2020

Tata India Pharma & Healthcare Fund(G)-Direct Plan

Top 10 Holdings
Company
(%)
DR REDDYs LABORATORIES LTD.
15.95
SUN PHARMACEUTICAL INDUSTRIES LTD.
15.22
DIVI LABORATORIES LTD.
10.88
LUPIN LTD.
9.51
IPCA LABORATORIES LTD.
7.00
ABBOTT INDIA LTD.
7.00
A) REPO
5.20
PROCTER & GAMBLE HEALTH LTD.
5.11
NARAYANA HRUDAYALAYA LTD.
4.87
CIPLA LTD.
3.62
Top 10 Sectors
Sectors
(%)
Pharmaceuticals & Drugs
83.75
Hospital & Healthcare Services
8.92
Miscellaneous
2.52
Asset Allocation
Market Cap Allocation
  Scheme Benchmark ()
Large-Cap 46.05 NA
Mid-Cap 38.13 NA
Small-Cap 15.82 NA

Best and Worst Performance and Ratios

Best Performance in a year
Period Fund (%) Benchmark (%)
Year 29/05/19
to 29/05/20
29.41NA
Worst Performance in a year
Period Fund (%) Benchmark (%)
Year 08/09/16
to 08/09/17
-17.32NA
Ratios
Standard Deviation[%] 27.64
Sharpe Ratio [%] 0.36
Turnover Ratio [%] 54.60
Modified Duration
YTM
Riskometer
high risk

Investors understand that their principal will be at high risk

Fund Details
Category
Sector Funds
Inception Date (Regular Plan)
28-Dec-15
Inception Date (Direct Plan)
28-Dec-15
Expense Ratio (Direct Plan) %
1.20
Expense Ratio (Regular Plan) %
2.60
Investing Style
Large Growth
Fund Manager
Meeta Shetty,Rahul Singh
Scheme Benchmark
AUM (Rs. in Cr.)
219.68
Fund Objective

Investment objective of the scheme is to provide long term capital appreciation by investing predominantly in equity/equity related instruments of the companies in the Pharma&Healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

Growth Chart of the Scheme Versus Benchmark (SIP value Rs10,000)
Tata India Pharma & Healthcare Fund(G)-Direct Plan

Performance Comparison with similar Schemes and Benchmark